messaggio

clik on the image and visit the new site

New site clik on the image

"In silico"


From Wikipedia
If the target host* of a phage therapy treatment is not an animal the term "biocontrol" (as in phage-mediated biocontrol of bacteria) is usually employed, rather than "phage therapy".

In silico
From:"Genomics,Proteomics and Clinical Bacteriology",N.Woodford and Alan P.Johnson

Phrase that emphasizes the fact that many molecular biologists spend increasing amounts of their time in front of a computer screen, generating hypotheses that can subsequently be tested and (hopefully) confirmed in the laboratory.


Phage Therapy is influenced by:

Phage therapy is influenced by:

Country : the epidemiological situation is different from country to country in terms of circulating bacteria and bacteriophages. Example: lytic phages from Italy may be no active on the same bacteria (genus and species) isolated from another country and vice versa.
Temporariness
Mutation rate
Phenotypical delay
Phage cocktail

My point of view

Sunday 8 May 2011

How does a person get infected with Mycobacterium marinum?



If Mycobacterium ulcerans is derived from Mycobacterium marinum it is possible to consider the hypothesis that many epidemiological aspects between these mycobacteria may be in common :for example the modality of transmission to the man.

There is a clear explanation in this site regarding the modality to infect the man by Mycobacterium marinum .

It is possible to apply more or less these information to Mycobacterium ulcerans.



From this site










The main difference between Mycobacterium ulcerans and Mycobacterium marinum is that Mycobacterium ulcerans produces a toxin (Mycolactone) which destroys tissue and suppresses the immune system.


See this post